Cargando…
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
OBJECTIVES: The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate. METHODS: We conducted a randomized, double-blinded, parallel, positive control design, multicenter study, with...
Autores principales: | Ye, Hua, Liu, Shengyun, Xu, Jian, Chai, Kexia, He, Dongyi, Fang, Yongfei, Xie, Qibing, Liu, Huaxiang, Liu, Ying, Hua, Bingzhu, Hu, Jiankang, Zhang, Zhiyi, Zhou, Mingxuan, Zhao, Dongbao, Li, Yan, Jiang, Zhenyu, Wang, Meimei, Li, Jingyang, Zhang, Zhuoli, Li, Xiaomei, Li, Yang, Sun, Erwei, Bi, Liqi, Wei, Wei, Tie, Ning, He, Lan, Huang, Xiangyang, Zhang, Yan, Huang, Qingchun, Wang, Xiaofei, Liu, Xiangyuan, Li, Jing, Su, Yin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140208/ https://www.ncbi.nlm.nih.gov/pubmed/36964872 http://dx.doi.org/10.1007/s40744-023-00544-2 |
Ejemplares similares
-
Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
por: An, Qing, et al.
Publicado: (2019) -
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
por: Su, Jinmei, et al.
Publicado: (2020) -
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points
por: Su, Jinmei, et al.
Publicado: (2020) -
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study
por: Su, Jinmei, et al.
Publicado: (2021) -
Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
por: Chen, Hanjing, et al.
Publicado: (2022)